Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Schiller on the Heterogeneity of AML

October 19th 2019

Gary J. Schiller, MD, discusses the heterogeneity of acute myeloid leukemia.

Rituximab Sets the Pace in Changing Lymphoma Landscape

October 18th 2019

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

FDA Label Update Supports Earlier Use of Romiplostim for ITP

October 18th 2019

The FDA has approved a supplemental Biologics License Application for romiplostim, updating its label to include data demonstrating sustained platelet responses in adults with immune thrombocytopenia. Romiplostim is approved for the treatment of adult patients with newly diagnosed or persistent who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in Myelofibrosis

October 17th 2019

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

Dr. Schiller on Venetoclax and Glasdegib in AML

October 17th 2019

Gary J. Schiller, MD, discusses the benefits and challenges of using venetoclax and glasdegib in patients with relapsed/refractory acute myeloid leukemia.

Polatuzumab Vedotin Offers a New Option for Refractory DLBCL

October 17th 2019

Jeff Sharman, MD, discusses the current approval and potential future roles for polatuzumab vedotin-piiq (Polivy) in diffuse large B-cell lymphoma.

Ruxolitinib Hits Primary Endpoint in Phase III Acute GVHD Trial

October 17th 2019

Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.

Breaking Down Developments in Benign Hematologic Malignancies

October 16th 2019

Daria V. Babushok, MD, PhD, provides insight into the latest developments in the treatment of patients with benign hematologic malignancies.

Measuring MRD Imperative to Guide ALL Treatment Decisions

October 16th 2019

Noelle Frey, MD, MS, highlights various therapies available to patients with acute lymphocytic leukemia and the importance of measuring minimal residual disease.

Investigators Aim at B-Cell Malignancies Using Targeted Radiopharmaceutical

October 16th 2019

In the phase II CLOVER-1 trial, investigators are evaluating whether CLR 131 will be an effective option for patients with difficult-to-treat relapsed or refractory B-cell lymphomas.

Novel Agents, Combo Regimens Poised to Dominate AML Treatment

October 15th 2019

Alexander Edward Perl, MD, MS, discusses advancements in acute myeloid leukemia treatment and future approaches in the field.

Lymphoma Advances Include Pivotal Trials, Novel Agents, and Effective Combos

October 14th 2019

Sunita Nasta, MD, discusses exciting updates in follicular lymphoma, diffuse large B-cell lymphoma, and T-cell lymphoma and the impact they will have on the upfront and relapsed/refractory paradigms.

Dr. Mesa on Ruxolitinib Vs Fedratinib in Myelofibrosis Treatment

October 12th 2019

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.

Hematologic Malignancy Research Gains Momentum at GW Cancer Center

October 11th 2019

Faculty from the George Washington Cancer Center to shed light on some of the current and future research efforts being made at their institution.

Role of MRD Still Evolving Across Hematologic Cancers

October 10th 2019

Imad Tabbara, MD, discusses the role of minimal residual disease testing in multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia, as well as emerging regimens in all 3 malignancies that are changing standards of care.

Dr. DiPersio on Investigational Targeted Cellular Therapies in AML

October 10th 2019

John F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.

Spreading Newfound Treatment Strategies in Hematologic Malignancies in Seattle

October 9th 2019

We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.

FDA Awards Research Grants for 12 Rare Diseases, Including GIST, AML, and Brain Tumors

October 9th 2019

The FDA has awarded 12 new research grants that together total more than $15 million, to enhance the development of medical products for patients with rare diseases, including acute myeloid leukemia and gastrointestinal stromal tumor, among others.

Making Headway in Hematologic Cancer Research at UCLA

October 8th 2019

Leading oncology experts at the University of California, Los Angeles share the pivotal research being conducted at their institution.

Dr. Perl on Choosing the Optimal Therapy in AML

October 2nd 2019

Alexander E. Perl, MD, MS, discusses how to assess what therapy is best for patients with acute myeloid leukemia.